BVF Partners Reaches Agreement with Oncothyreon Regarding Board Representation and CEO Search

Firm News

As previously announced, Olshan client BVF Partners reached an agreement with Oncothyreon, a clinical-stage biopharmaceutical company, regarding changes to the Company’s board composition and the search for a new CEO. In connection with the agreement with BVF Partners, Oncothyreon announced that its CEO has resigned and that the Company would commence a CEO search process.  The agreement called for the immediate appointment of Gwen Fyfe, M.D., a highly-regarded member in the biopharmaceutical field, and BVF’s founder Mark Lampert.  Pursuant to the agreement, the Board established a three-member CEO search committee, which includes Mr. Lampert, to oversee and identify a new CEO.  Olshan represented BVF Partners in connection with their activist campaign at Oncothyreon.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.